Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s designed to work differently from those currently on the market and with the potential for fewer side effects.
Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ingredients that may lack the purity of the branded medications.
3d
on MSN
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
4d
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
10d
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Verywell Health on MSN
3d
Zepbound (Tirzepatide) vs. Wegovy (Semaglutide): How Do They Compare?
These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...
1d
on MSN
FDA to review removal of Eli Lilly weight loss drug from shortage list
FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...
11d
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
ConsumerAffairs
10d
Mountjaro, Zepbound removed from FDA's shortage list
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Managed Healthcare Executive
1d
Are PBMs Putting GLP-1 Drugs on Their Formularies?
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
2d
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
10d
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Eli Lilly
Mounjaro
Tirzepatide
weight loss drugs
Ozempic
Feedback